Oculis Aktie 124230349 / CH1242303498
14.75
USD
-0.11
USD
-0.74%
21.11.2024
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Oculis Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | Oculis Holding AG | 0.00 | 0.00 | USD |
| 2022 | Oculis Holding AG | 0.00 | 0.00 | USD |
| 2021 | Oculis Holding AG | 0.00 | 0.00 | USD |
Zu diesem Datensatz liegen uns leider keine Daten vor.
Oculis Holding AG Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Oculis Holding AG | Quartalszahlen | 24.03.2025 |
| Oculis Holding AG | Quartalszahlen | 07.05.2025 |
| Oculis Holding AG | Quartalszahlen | 02.09.2025 |
| Oculis Holding AG | Quartalszahlen | 07.11.2025 |
Oculis Holding AG vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q3 2024 Earnings Release | 07.11.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 27.08.2024 |
| Hauptversammlung | Annual General Meeting | 29.05.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 08.05.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 18.03.2024 |
| Quartalszahlen | Q2 2023 Earnings Release | 29.08.2023 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 59.81 |
| LSP Management Group BV | 12.76 |
| Brunnur Ventures GP ehf | 5.60 |
| Shanghai Bioveda Investment Management Consulting Co. Ltd. | 4.96 |
| Pivotal Bioventure Partners Investment Advisor LLC | 4.87 |
| Martijn Kleijwegt | 4.78 |
| Novartis AG | 4.10 |
| Tekla Capital Management LLC | 4.05 |
| Pivotal Bioventure Partners Investment Advisor LLC | 3.82 |
| Glazer Capital LLC | 3.01 |
| Riad Sherif, MD, MBA | 2.10 |
| abrdn, Inc. | 1.97 |
| Periscope Capital, Inc. | 1.86 |
| Millennium Management LLC | 1.42 |
| Macquarie Group Ltd. (13F Subfiler) | 1.21 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Personal am Ende des Jahres | 2 | 28 | 36 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.00 | 0.00 | 0.00 |
Bilanz (in Mio. USD) - Aktiva
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Summe Umlaufvermögen | 1 | 26 | 120 |
| Summe Anlagevermögen | 128 | 14 | 16 |
| Summe Aktiva | 128 | 40 | 136 |
Bilanz (in Mio. USD) - Passiva
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 0 | 133 | 1 |
| Summe Fremdkapital | 8 | 146 | 25 |
| Summe Eigenkapital | 121 | -106 | 111 |
| Summe Passiva | 128 | 40 | 136 |
Adresse
| Bahnhofstrasse 7, 6300 Zug | |
| Telefon | +41 (58) 810-01-82 |
| URL | http://oculis.com |
Management
|
Anthony Adam Rosenberg
Chairman |
|
Arshad M. Khanani
Director |
|
Bastian Dehmel
Chief Development Officer |
|
Christina Maria Ackermann
Independent Director |
|
Daniel S. Char
Chief Legal Officer |
|
Geraldine O'Keeffe
Independent Director |
|
Lionel Carnot
Independent Director |
|
Martijn Kleijwegt
Independent Director |
|
Páll Ragnar Jóhannesson
Chief Business Officer |
|
Ramin Tadayoni
Chief Scientific Officer |
|
Rebecca Weil
Chief Commercial Officer |
|
Riad Sherif
Chief Executive Officer & Director |
|
Robert K. Warner
Director |
|
Sharon Klier
Chief Development Officer |
|
Snehal Shah
President-Research & Development |
|
Sylvia Cheung
Chief Financial Officer |
|
Virginia R. Dean
Chief Human Resources Officer |